A5044691449- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemophilia Treatment and Research
- Urticaria and Related Conditions
- Mast cells and histamine
- Autoimmune Bullous Skin Diseases
- Chronic Myeloid Leukemia Treatments
- PI3K/AKT/mTOR signaling in cancer
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Asthma and respiratory diseases
- Vitamin K Research Studies
- Eosinophilic Disorders and Syndromes
- Immune Cell Function and Interaction
- Music Therapy and Health
- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Infant Development and Preterm Care
- IL-33, ST2, and ILC Pathways
- Enzyme function and inhibition
- Allergic Rhinitis and Sensitization
- Blood Coagulation and Thrombosis Mechanisms
- Neuroscience and Music Perception
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Myasthenia Gravis and Thymoma
- Pediatric health and respiratory diseases
University of California, Los Angeles
2014-2024
Providence College
2023-2024
St. John Medical Center
2023-2024
Ionis Pharmaceuticals (United States)
2024
Children's Music Fund
2023-2024
Children's Defense Fund
2024
Saint John's Health Center
2023
UCLA Health
2006-2023
University of Santa Monica
2017-2023
Pacific Northwest University of Health Sciences
2022
Since 1990, the reported incidence of pertussis has increased in United States with peaks occurring every 3-4 years. On basis analysis cases to Centers for Disease Control and Prevention, remained stable among children aged younger than 5 years, most whom were protected by vaccination. In contrast 1990-1993, during 1994-1996, average persons 5-9 10-19 20 years or older 40%, 106%, 93%, respectively. 14 states incidences > =2 per 100,000 population at least 4 between 1990 1996; seven these...
Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, preventing attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites Canada, Europe, Jordan, and United States. Patients were randomized between March 2016, September 9, 2016; last day follow-up was April 13, 2017. Randomization 2:1...
BackgroundBerotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis hereditary angioedema (HAE) attacks.ObjectiveOur aim was to determine efficacy, safety, and tolerability berotralstat patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial).MethodsAPeX-2 double-blind, parallel-group study that randomized at 40 sites 11 countries 1:1:1 receive dose 110 mg or 150 placebo (Clinicaltrials.gov identifier NCT03485911)....
Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling potentially fatal. Selective inhibition of plasma prekallikrein production antisense oligonucleotide treatment (donidalorsen) may reduce the frequency attacks burden disease.
Hereditary angioedema is a rare disorder characterized by episodic, potentially life-threatening swelling caused kallikrein-kinin dysregulation. Long-term prophylaxis can stabilize this system. Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression.
Polymorphisms in the interleukin-4 receptor α chain (IL-4Rα) have been linked to asthma incidence and severity, but a causal relationship has remained uncertain. In particular, glutamine arginine substitution at position 576 (Q576R) of IL-4Rα associated with severe asthma, especially African Americans. We show that mice carrying Q576R polymorphism exhibited intense allergen-induced airway inflammation remodeling. The did not affect proximal signal transducer activator transcription (STAT) 6...
Symptoms of hereditary angioedema (HAE) typically first present during childhood, but the frequency/severity attacks often increases at puberty. Real-world data on long-term HAE prophylaxis in adolescents are limited. We report pooled from adolescent patients enrolled two Phase 4 studies (EMPOWER, ENABLE) evaluating effectiveness/safety lanadelumab (monoclonal antibody directed against plasma kallikrein) for prevention attacks. Adolescent (aged 12 to <18 years) with HAE-C1INH EMPOWER and...